# Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery

> **NCT05844371** · PHASE2 · UNKNOWN · sponsor: **Yixing People's Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** tirelizumab
- **DRUG:** chemotherapy with oxaliplatin + heroda

## Key facts

- **NCT ID:** NCT05844371
- **Lead sponsor:** Yixing People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2023-06-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05844371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05844371, "Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05844371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*